Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
| ▸ | HTR1D | P28221 | 5/20 | 0.42 |
| ▸ | HTR1B | P28222 | 5/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5342075 | 0.86 | HTR1A (0.46) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL5348212 | 0.81 | KDM4E (0.44) | KDM4EPKMHTR1AHTR1DHTR1B | |
| SCHEMBL5346023 | 0.77 | NMT1 (0.48) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL16112711 | 0.74 | KDM4E (0.58) | KDM4EPKMGPR119TGFBR1 | |
| SCHEMBL1405373 | 0.74 | KDM4E (0.57) | KDM4EPKMGPR119TGFBR1 | |
| SCHEMBL3172041 | 0.73 | MAPT (0.57) | KDM4EPKMGPR119 | |
| SCHEMBL16825244 | 0.73 | GPR119 (0.60) | KDM4EPKMGPR119 | |
| SCHEMBL23119230 | 0.72 | KDM4E (0.55) | KDM4EPKMGPR119TGFBR1 | |
| SCHEMBL3881471 | 0.72 | KDM4E (0.58) | KDM4EPKMGPR119TGFBR1 | |
| SCHEMBL4572383 | 0.72 | CTSD (0.44) | UTS2RKDM4EGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214674-B2 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-20050153974-A1 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153974-A1 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | HTR1A, HTR1D, HTR2C | UTS2R 846/4885KDM4E 1328/4885PKM 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.